home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Risk Analysis for Portfolio of Drug Development Programs - Webinar By GlobalCompliancePanel

 
  January 05, 2012  
     
 
GlobalCompliancePanel, Online Training
2012-02-02


 Building in strategic risk scenarios into portfolio planning can buffer the organization against the unexpected. Examples might be clinical trial failure, shifts in the marketplace or insufficient resource capacity. This webinar covers various portfolio planning tools and techniques with a focus on strategic risk management. 

Key Questions to Be Addressed:
  • How to align strategic goals and available resources? 
  • What strategic risks company should be prepared for?
  • How to incorporate risk in portfolio planning? 
  • What tools could be used for portfolio planning to analyze portfolio selection, capacity planning and risk management? 
  • How to simulate risk mitigation strategies?
Why you should attend: Neglecting risk assessment in portfolio planning could ruin company strategy. Major source of uncertainty is outcome of clinical trial. Another source is marketing predictions. Therefore, portfolio planning based on averages, could mislead executive management. Some companies use simplistic risk assessment portfolio models. They do not take into account interdependencies between drug development projects. Unfortunately, those models are inaccurate, and generate misleading results.

Areas Covered in the Session:
  • What strategic risks company should be prepared for?
  • How to incorporate risk in portfolio planning? 
  • What tools could be used for portfolio planning to analyze portfolio selection, capacity planning and risk management? 
  • How to simulate risk mitigation strategies?
Who Will Benefit:
  • Portfolio planning, VP, Director, manager
  • Financial analysts, Directors, VPs, managers
  • Clinical Operations, VP, Director, planner, manager
  • Business Development, VP, Director, analyst, manager
  • Discovery portfolio, VP, Director, manager
  • Manufacturing, VP, Director, manager
  • Marketing, VP, Director Manager
 
Price List:
Live : $245.00
Corporate live : $995.00
Recorded : $295.00

webinars@globalcompliancepanel.com
http://www.globalcompliancepanel.com

Phone: 800-447-9407
Fax: 302-288-6884

 
 
 
Organized by: GlobalCompliancePanel
Invited Speakers:
Vladimir Shnaydman, Ph.D, is President of ORBee Consulting. Vladimir has BS & MS Electrical Engineering & Computer Science, MS in Applied Mathematics & Operations Research, and Ph.D. in Engineering. He contributed to many industries such as biotechnology, computer networking, data storages, water resources planning and management, telecommunications, transportation, and others. Dr. Shnaydman published more than 50 papers. He is co-author of three books
 
Deadline for Abstracts: 2012-02-01
 
Registration:
webinars@globalcompliancepanel.com
http://www.globalcompliancepanel.com

Phone: 800-447-9407
Fax: 302-288-6884
E-mail: globalcompliancepanel@gmail.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.